Further, in this study of 32 Chinese patients with NSCLC harboring major uncommon EGFR mutations treated with dacomitinib, 14 patients (46.7%) showed disease progression within a median follow-up duration of 11.4 months. Here, EGFR is linked to non-small cell lung carcinoma.